Sesen Bio (NASDAQ:SESN) Stock Slumps 80% in a Week: What’s The Buzz?
Sesen Bio (NASDAQ:SESN) down 79% in a week after the US FDA told the company that it would not be approving its BLA for Vicineum, the company’s bladder cancer treatment. The sell-off experienced following the news made sense since Vicineum is part of every pipeline program of the company, combination therapy or alone. Usually, investors overreact to negative or positive development. However, the stock seems to be bouncing back, which…









